Home
Home

M&A

Optimer Said to Draw Takeover Interest From Glaxo, Astellas

Optimer Said to Draw Takeover Interest From Glaxo, Astellas
Bloomberg

Biotech M&A deals dominate key Q1 metric

Biotech M&A deals dominate key Q1 metric
Fierce Biotech

Should AstraZeneca and Bristol-Myers Squibb Get Married?

Should AstraZeneca and Bristol-Myers Squibb Get Married?
Motley Fool

Is Acadia An Acquisition Target?

Is Acadia An Acquisition Target?
Seeking Alpha

Shire to Buy Eye-Drug Maker SARcode for $160 Million

Shire to Buy Eye-Drug Maker SARcode for $160 Million
Bloomberg

Obagi Medical Sued by Investor Over $360 Million Offer

Obagi Medical Sued by Investor Over $360 Million Offer
Bloomberg

Theravance Seen Luring Glaxo Bid as Drugs Near FDA Nod: Real M&A

Theravance Seen Luring Glaxo Bid as Drugs Near FDA Nod: Real M&A
Bloomberg

Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind

Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind
Seeking Alpha

3SBio Inc. Announces Extraordinary General Meeting of Shareholders

3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Yahoo/PR Newswire

Valeant Buying Obagi Medical; Both Stocks Jump By AMY REEVES, INVESTOR'S BUSINESS DAILY

Valeant Buying Obagi Medical; Both Stocks Jump
Investors.com